The increase in the Severe Asthma market size is a direct consequence of the expected launch of potential therapies an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies.<\/p>\n
LAS VEGAS, June 8, 2022 \/PRNewswire\/ -- DelveInsight's Severe Asthma Market Insightsreport proffers a detailed comprehension of Severe Asthma market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Severe Asthma market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).<\/p>\n
Some of the salient features from the Severe Asthma Market Report:<\/p>\n
For further information on market impact by therapies, download the Severe Asthmamarket sample @ Severe Asthma Therapeutics Market Scenario<\/p>\n
Severe Asthma Overview<\/p>\n
Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodelling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction. The characteristic Asthma symptoms include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate.<\/p>\n
Asthma classification can be broadly done into intermittent or persistent. Here, Persistent asthma is further sub-divided based on severity into mild, moderate, and severe. Severe Asthma occurs due to various genetic, environmental, and psychological factors as well as respiratory infections. Severe Asthma symptoms appear often in the nighttime with a persistent airflow obstruction with a forced expiratory volume (FEV1) of less than 60% predicted before treatment.<\/p>\n
Based upon response to treatment, Severe Asthma is further classified into type-2 inflammation and non-type-2 inflammation. Type-2 inflammation includes allergic asthma and eosinophilic asthma (or e-asthma) while non-type-2 inflammation includes non-eosinophilic asthma.<\/p>\n
Severe Asthma Epidemiology Segmentation<\/p>\n
As per the assessment of DelveInsight, the total diagnosed prevalent (adult + pediatric) cases of Asthma in the 7MM was observed to be approximately 54 million cases in 2021. These cases are expected to increase by 2032.<\/p>\n
As per DelveInsight's estimates, among 7MM, the United States had the highest diagnosed cases of adult Asthma with almost 20 million cases in 2021.<\/p>\n
The Severe Asthma Market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into<\/p>\n
Learn more about the Severe Asthma Population Trends for the 7 MM by downloading@ Severe AsthmaEpidemiology Forecast Report<\/p>\n
Severe Asthma Market Outlook<\/p>\n
The fundamental goal of Asthma therapy is to minimize airway inflammation and also reduce the Asthma symptoms that come with it. To limit the likelihood of exacerbation, guidelines-based care focuses on illness severity and selecting the right medicinal therapy. Inhaled corticosteroids are the most common chronic asthma treatment, but quick-relief (reliever) or rescue medications are frequently used to reduce acute Asthma symptoms. Short-acting beta-agonists (SABAs) relieve airway bronchoconstriction quickly and are indicated as a symptom-relieving rescue drug. If asthma still isn't under control, long-acting beta 2 agonists (LABA), montelukast, or theophylline are added. If Asthma symptoms and flare-ups persist, oral corticosteroids are prescribed.<\/p>\n
There are currently six US FDA approved monoclonal antibodies for add-on biological Severe Asthma treatment. They include Cinqair (reslizumab) Teva Pharmaceutical, Dupixent (dupilumab) Sanofi, and Regeneron, Fasenra (benralizumab) AstraZeneca\/Kyowa Kirin, Tezspire (tezepelumab) AstraZeneca and Amgen, Nucala (mepolizumab) GlaxoSmithKline, and Xolair (omalizumab) Novartis\/Genentech.<\/p>\n
Several new severe asthma therapeutic options are currently being developed. The key assets include GSK3511294 (Depemokimab) by GlaxoSmithKline, PT010 (Breztri\/Trixeo\/BGF MDI (budesonide-glycopyrrolate-formoterol inhalation)) by AstraZeneca, and PT027 (BDA MDI\/Budesonide\/albuterol sulfate metered-dose inhaler) by AstraZeneca and Bond Avillion. They are in the late stage of development and are expected to launch in the forecasted period (2022-2032). Several other companies are also developing drugs for Severe Asthma treatment including Novartis (CSJ117), 4D pharma (MRx-4DP0004), Roche (RG6173), Pieris Pharma, and AstraZeneca (PRS-060\/AZD1402), Biosion (BSI-045B), among others.<\/p>\n
Discover more about therapy set to grab substantial Severe Asthmamarket share @ Severe Asthma Market Landscape<\/p>\n
Severe AsthmaPipeline Therapies and Key Companies<\/p>\n
To know about more pipeline therapies covered in the report, visit @ Severe AsthmaPipeline Analysis, Clinical Trials, and Emerging Therapies<\/p>\n
Severe AsthmaMarket Dynamics<\/p>\n
Severe Asthma market growth in the coming years is dependent on several factors such as an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies. Also, the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for patients will drive the Severe Asthma market growth in the forecast period. In addition to that, approvals and entry of new drugs will change the Severe Asthma market dynamics in the future. Several pharmaceutical giants are investigating drugs for Severe Asthma treatment with an improved diagnostic approach leading to a rise in the Severe Asthma market in the coming years.<\/p>\n
On the other hand, a lack of effective specific treatments in non-eosinophilic asthma (NEA) can represent an orphan asthma endotype serving as a drawback in the Severe Asthma market growth. Other factors such as a high cost of treatment, limitations in diagnosis, incorrect inhaler techniques, and poor adherence to treatment can all be considered as potential barriers to the rise of the Severe Asthma market.<\/p>\n
Know which therapy is expected to score the touchdown first @ Severe Asthma Market Landscape and Forecast<\/p>\n
Scope of the Severe Asthma Market Report<\/p>\n
Request for a Webex demo of the report @ Severe Asthma Therapeutics Market<\/p>\n
Table of Contents<\/p>\n
1<\/p>\n
Key Insights<\/p>\n
2<\/p>\n
Report Introduction<\/p>\n
3<\/p>\n
Severe Asthma Market Overview at a Glance<\/p>\n
4<\/p>\n
Executive Summary of Severe Asthma<\/p>\n
5<\/p>\n
Severe Asthma Epidemiology and Market Methodology<\/p>\n
6<\/p>\n
Severe Asthma: Disease Background and Overview<\/p>\n
7<\/p>\n
Diagnosis of Severe Asthma<\/p>\n
8<\/p>\n
Severe Asthma Treatment<\/p>\n
9<\/p>\n
Conclusion for Severe Asthma<\/p>\n
10<\/p>\n
Severe Asthma Epidemiology and Patient Population<\/p>\n
11<\/p>\n
Severe Asthma Patient Journey<\/p>\n
12<\/p>\n
Key Endpoints in Severe Asthma Clinical Trials<\/p>\n
13<\/p>\n
Severe Asthma Marketed Therapies<\/p>\n
14<\/p>\n
Severe Asthma Emerging Therapies<\/p>\n
15<\/p>\n
Severe Asthma: 7 Major Market Analysis<\/p>\n
16<\/p>\n
Market Access and Reimbursement<\/p>\n
17<\/p>\n
KOL Views<\/p>\n
18<\/p>\n
Severe Asthma Market Drivers<\/p>\n
19<\/p>\n
Severe Asthma Market Barriers<\/p>\n
20<\/p>\n
Severe Asthma SWOT Analysis<\/p>\n
21<\/p>\n
Severe Asthma Unmet Needs<\/p>\n
22<\/p>\n
Appendix<\/p>\n
23<\/p>\n
DelveInsight Capabilities<\/p>\n
24<\/p>\n
Disclaimer<\/p>\n
25<\/p>\n
About DelveInsight<\/p>\n
Get in touch with our Business executive @Severe Asthma Market Landscape Analysis<\/p>\n
Related Reports<\/p>\n
Asthma Market<\/p>\n
DelveInsight's \"Asthma Market Insights, Epidemiology, and Market Forecast-2032\" report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n
Allergic Asthma due to Dermatophagoides Farinae Market<\/p>\n
DelveInsight's \"Allergic Asthma due to Dermatophagoides Farinae- Market Insights, Epidemiology, and Market Forecast-2032\" report delivers an in-depth understanding of the Allergic Asthma due to Dermatophagoides Farinae, historical and forecasted epidemiology, current Allergic Asthma due to Dermatophagoides Farinae treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n
Eosinophilic Asthma Market<\/p>\n
DelveInsight's \"Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2032\" report delivers an in-depth understanding of the Eosinophilic Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n
Asthma Epidemiology<\/p>\n
DelveInsight's 'Asthma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n
Pulse Oximeters Market<\/p>\n
DelveInsight's 'Pulse Oximeters Market Insights, Competitive Landscape and Market Forecast - 2027' report deliver an in-depth understanding of Pulse Oximeters, historical and forecasted Pulse Oximeters market trends, market drivers, market barriers, and key companies involved like Medtronic, Nonin Medical Inc, Lepu Medical Technology, TytoCare Ltd, VYAIRE, OMRON Corporation. Meditech Equipment Co ., Ltd, and several others.<\/p>\n
Cough Assist Devices Market<\/p>\n
\"DelveInsight's 'Cough Assist Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Cough Assist Devices and the historical and forecasted Cough Assist Devices market trends, market drivers & barriers, unmet needs and key companies involved such as Koninklijke Philips N.V, Percussionaire Corp., Emerson, Hill Rom, Dima Italia SRL, and many more.<\/p>\n
Cough in Idiopathic Pulmonary Fibrosis Market<\/p>\n
DelveInsight's 'Cough in Idiopathic Pulmonary Fibrosis (IPF)-Market Insights, Epidemiology and Market Forecast 2032' report delivers an in-depth understanding of the cough in IPF, historical and forecasted epidemiology as well as the Cough in IPF market trends, market drivers & barriers, unmet needs and key companies involved such as Algernon Pharmaceuticals, Trevi Therapeutics, Nerre Therapeutics, and others.<\/p>\n
Chronic Obstructive Pulmonary Disease Market<\/p>\n
DelveInsight's 'Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast2032' report deliver an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends, market drivers & barriers, unmet needs and key companies involved such as AstraZeneca, Amgen, Circassia Pharmaceuticals Inc, Biomarck Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Genentech, GlaxoSmithKline, Theravance, Innoviva, Inmunotek, Mereo BioPharma, Novartis Pharmaceuticals, and several others.<\/p>\n
Asthma Diagnostic Devices Market<\/p>\n
\"DelveInsight's 'Asthma Diagnostic Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Asthma Diagnostic Devices and the historical and forecasted Asthma Diagnostic Devices market trends, drivers, barriers, and key companies involved such as Medline Industries, Becton, Dickinson and Company, Siemens Process Instrumentation, Smiths Medical, Vyaire Medical, Nihon Kohden Corporation, Vitalograph, Circassia Limited, Intermedical (UK) Limited, and several others.<\/p>\n
Chronic Obstructive Pulmonary Disease Treatment Devices Market<\/p>\n
\"DelveInsight's 'Chronic Obstructive Pulmonary Disease Treatment Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease Treatment Devices and the historical and forecasted Chronic Obstructive Pulmonary Disease Treatment Devices market trends, drivers, barriers and key companies involved such as GlaxoSmithKline plc, Novartis AG, Merck & Co., Koninklijke Philips N.V, AstraZeneca, 3M, GF HEALTH PRODUCTS, Sunovion Pharmaceuticals Inc, Smiths Medical, Baxter, and others.<\/p>\n
Interested to know more about the breakthrough happenings? Take a look at the posts below<\/p>\n
<\/p>\n
Original post: <\/p>\n
Severe Asthma Market to Progress Upto USD 7 Billion by 2032 | DelveInsight - PR Newswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" The increase in the Severe Asthma market size is a direct consequence of the expected launch of potential therapies an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies. LAS VEGAS, June 8, 2022 \/PRNewswire\/ -- DelveInsight's Severe Asthma Market Insightsreport proffers a detailed comprehension of Severe Asthma market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Severe Asthma market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). Some of the salient features from the Severe Asthma Market Report: For further information on market impact by therapies, download the Severe Asthmamarket sample @ Severe Asthma Therapeutics Market Scenario Severe Asthma Overview Asthma is the most common chronic respiratory disease all over the globe. Continue reading